Clinical study started with Biotie's proprietary VAP-1 antibody in psoriasis patients

BIOTIE THERAPIES CORP.  STOCK EXCHANGE RELEASE  March 27, 2009 at
8.15 a.m.



Clinical study started with Biotie's proprietary VAP-1 antibody in
psoriasis patients

Biotie has started a clinical trial with its fully human VAP-1
monoclonal antibody (BTT-1023) in psoriasis patients. The study will
be conducted within the European Union and will evaluate the safety,
tolerability, and pharmacokinetics of repeated doses of intravenously
administered antibody in up to 36 patients with psoriasis. Results
are expected in the first half of 2010.

The initiated study, together with the previously commenced study in
rheumatoid arthritis patients, is expected to establish a basis for
designing full-scale therapeutic studies and to provide initial
information on the therapeutic potential of the antibody in these
inflammatory conditions.

In November 2006, Biotie and Roche had signed an option agreement for
the antibody program targeting VAP-1. Under the terms of the
agreement, Roche had paid an option initiation fee of EUR 5 million,
which granted Roche an exclusive option right to an exclusive,
worldwide license agreement for Biotie's fully human antibody
targeting VAP-1, excluding Japan, Taiwan, Singapore, New Zealand, and
Australia. The initial option right will end upon completion of Phase
I, and it is expected that this point will be reached when one of the
now ongoing studies is completed. Biotie will retain all rights to
the program until a license is granted to Roche.


Turku, March 27, 2009

Biotie Therapies Corp.


Timo Veromaa
President and CEO



For further information, please contact:

Antero Kallio, Chief Medical Officer
Tel. +358 2 274 8900, e-mail: antero.kallio@biotie.com

Virve Nurmi, Investor Relations Manager
tel. +358 2 274 8911, e-mail: virve.nurmi@biotie.com

www.biotie.com

Distribution:
NASDAQ OMX Helsinki Ltd
Main Media